2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow Urothelial Carcinoma Bladder: new trials by email Literature Review of Urothelial Carcinoma Bladder trials Research Report on Urothelial Carcinoma Bladder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC IO102-IO103 in combination with pembrolizumab - Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma | Phase 2 | Completed | IO Biotech | 63 | 2022-04-11 | 2026-04-08 |
| A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer UGN-102 - Bladder Cancer, Urothelial Carcinoma | Phase 2 | Completed | UroGen Pharma Ltd. | 63 | 2018-10-15 | 2022-09-16 |
Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Urinary Bladder Neoplasms (1)
Carcinoma (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Squamous Cell (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Head and Neck Neoplasms (1) · Lung Diseases (1) · Lung Neoplasms (1) · Male Urogenital Diseases (1) · Respiratory Tract Diseases (1)
Mitomycin (1) · pembrolizumab (1)
IO Biotech (1) · UroGen Pharma Ltd. (1)
United States (2) · Israel (1) · Spain (1) · United Kingdom (1)
Elyse Seltzer, MD (1) · Jonathan W Riess, MD, MSc (1)